BamSEC and AlphaSense Join Forces
Learn More

Phathom Pharmaceuticals Inc. – Material Contracts

NASDAQ: PHAT    
Share price (9/11/26): $8.36    
Market cap (9/11/26): $676 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 4 pages Phathom Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.1
from 10-Q 4 pages 2nd Amendment to the Supply and Packaging Services Agreement Dated December 30, 2020
12/34/56
EX-10.19
from 10-K 62 pages Revenue Interest Financing Agreement
12/34/56
EX-10.1
from 10-Q 16 pages Re: Employment Offer Letter Dear Sanjeev: Phathom Pharmaceuticals, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”). • Start Date. We Expect That Your Employment Start Date (The “Start Date”) Will Occur on or About October 6, 2025 • Employment Terms
12/34/56
EX-10.3
from 10-Q 26 pages Re: Employment Offer Letter Dear Anne Marie, Phathom Pharmaceuticals, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”). • Start Date. We Expect That Your Employment Start Date (The “Start Date”) Will Occur on or About June 23, 2025. • Employment Terms
12/34/56
EX-10.2
from 10-Q 27 pages Separation Agreement and Release of Claims
12/34/56
EX-10.1
from 10-Q 39 pages Separation Agreement and Release of Claims
12/34/56
EX-10.2
from 10-Q 14 pages Separation Agreement and Release of Claims
12/34/56
EX-10.1
from 10-Q 17 pages Steve Basta Re: Employment Offer Letter Dear Steve: Phathom Pharmaceuticals, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”). • Employment Terms. O
12/34/56
EX-10.1
from S-8 32 pages Phathom Pharmaceuticals, Inc. 2025 Employment Inducement Incentive Award Plan
12/34/56
EX-10.30
from 10-K 4 pages Joinder Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Phathom Pharmaceuticals, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Phathom Pharmaceuticals, Inc. if Publicly Disclosed. 4 September 2024 Phathom Pharmaceuticals, Inc Theresa Ledbetter 100 Campus Drive, Suite 102 Evonik Corporation Florham Park, Nj 07932 Director, Key Account Management and Sales Drug Substance
12/34/56
EX-10.1
from 10-Q 4 pages Phathom Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.28
from 10-K/A 7 pages Phathom Pharmaceuticals Bonus Plan Effective January 1, 2024
12/34/56
EX-10.26
from 10-K/A 5 pages First Amendment to Commercial Supply Agreement
12/34/56
EX-10.28
from 10-K 7 pages Phathom Pharmaceuticals Bonus Plan Effective January 1, 2024
12/34/56
EX-10.26
from 10-K 5 pages First Amendment to Commercial Supply Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Phathom Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.1
from 10-Q 5 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. the Omissions Have Been Indicated by “[***].” Amendment No. 1 to Vonoprazan Commercial Supply Agreement
12/34/56
EX-10
from 10-K 12 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. the Omissions Have Been Indicated by “[***].” Joinder and Waiver Agreement
12/34/56